Antisense oligonucleotide therapeutics for iron–sulphur cluster deficiency myopathy

Abstract 

Iron–sulphur cluster deficiency myopathy is caused by a deep intronic mutation in ISCU resulting in inclusion of a cryptic exon in the mature mRNA. ISCU encodes the iron–sulphur cluster assembly protein IscU. Iron–sulphur clusters are essential for most basic redox transformations including the respiratory-chain function. Most patients are homozygous for the mutation with a phenotype characterized by a non-progressive myopathy with childhood onset of early fatigue, dyspnoea and palpitation on trivial exercise. A more severe phenotype with early onset of a slowly progressive severe muscle weakness, severe exercise intolerance and cardiomyopathy is caused by a missense mutation in compound with the intronic mutation. Treatment of cultured fibroblasts derived from three homozygous patients with an antisense phosphorodiamidate morpholino oligonucleotide for 48h resulted in 100% restoration of the normal splicing pattern. The restoration was stable and after 21days the correctly spliced mRNA still was the dominating RNA species.

Keywords: Iron–sulphur cluster deficiency myopathy ISCU, Antisense oligonucleotide treatment, Morpholino, Phosphorodiamidate morpholino oligonucleotide (PMO), Deep intronic mutation